Brain Cancer Diagnostics Market Size, Share and Growth Outlook, 2026

Brain Cancer Diagnostics Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Brain Cancer Diagnostics Market size is forecast to increase from $2.09 Billion in 2026 to $3.81 Billion in 2034 at a CAGR of 7.8% between 2026 and 2034.

The Brain Cancer Diagnostics market report provides detailed analysis and outlook of Brain Cancer Diagnostics segments including By Product (Instruments and Imaging Systems, Reagents, Probes, and Kits, Diagnostic and Testing Services, Software and Maintenance Support), By Diagnostic Test Type (Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, Computed Tomography, Positron Emission Tomography, Biopsy and Tissue Sampling, Lumbar Puncture, Biomarker and Molecular Testing ), By Tumor Type Focus (Primary Brain Tumors, Secondary ), By Application (Initial Screening and Clinical Diagnosis, Treatment Monitoring and Response Assessment, Prognostic Biomarker Identification), By End-User (Hospitals and Radiology Departments, Specialized Cancer Treatment & Oncology Centers, Diagnostic Laboratories and Pathology Testing Centers, Academic and Cancer Research Institutes) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Brain Cancer Diagnostics Industry Overview

Advancements in Precision Neurodiagnostics Transforming Brain Tumor Detection

The brain cancer diagnostics industry is undergoing rapid transformation as healthcare providers increasingly adopt advanced imaging, molecular profiling, and artificial intelligence technologies to improve the detection and characterization of brain tumors. Accurate diagnosis is essential for determining treatment pathways, surgical planning, and patient prognosis in cases involving gliomas, meningiomas, metastatic brain tumors, and other central nervous system malignancies. The integration of functional imaging, genomic analysis, and molecular classification platforms is enabling clinicians to achieve higher diagnostic precision while supporting personalized neuro-oncology care.

Artificial Intelligence Enhancing Pre-Surgical Brain Mapping

Artificial intelligence is becoming a critical component of modern brain cancer diagnostics, particularly in surgical planning applications. A significant industry development was the FDA 510(k) clearance granted to Sora Neuroscience for its Cirrus Resting State fMRI Software. The AI-driven platform utilizes functional magnetic resonance imaging data to map localized and essential brain networks, enabling neurosurgeons to accurately distinguish between malignant gliomas, surrounding edema, and healthy brain tissue before cranial resection procedures. Such innovations improve surgical decision-making, help preserve neurological function, and support more precise tumor removal strategies in complex neuro-oncology cases.

Molecular Classification Revolutionizing Tumor Subtyping

The growing adoption of molecular diagnostics is reshaping the way central nervous system tumors are identified and classified. The German Cancer Research Center (DKFZ) deployed the latest version of its Heidelberg CNS Tumor Methylation Classifier, an advanced platform that utilizes DNA methylation signatures to classify more than 180 distinct central nervous system tumor types. The enhanced system doubles the diagnostic capability of earlier versions and has demonstrated superior performance compared with conventional histopathological evaluation. This advancement highlights the increasing importance of molecular profiling technologies in improving diagnostic accuracy, reducing classification uncertainty, and supporting precision medicine approaches in neuro-oncology.

Portable Imaging Expanding Access to Rapid Neuro-Oncology Assessment

Innovation in imaging infrastructure is further strengthening the brain cancer diagnostics market. Hyperfine launched the global commercial rollout of its updated Swoop portable low-field magnetic resonance imaging system, designed specifically for intensive care units and emergency departments. The mobile imaging platform allows clinicians to perform neuroimaging directly at the patient's bedside, facilitating rapid assessment of intracranial neoplasms and primary brain tumor pathology without the need to transport critically ill patients to conventional MRI suites. The increasing adoption of portable neuroimaging technologies is improving diagnostic accessibility, accelerating clinical decision-making, and expanding point-of-care capabilities within brain cancer management.

Brain Cancer Diagnostics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Brain Cancer Diagnostics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- GE HealthCare, Siemens Healthineers AG, Koninklijke Philips N.V., Roche Diagnostics (F. Hoffmann-La Roche), Thermo Fisher Scientific Inc., Illumina, Inc., Abbott Laboratories, Agilent Technologies, Inc., Hologic, Inc., Fujifilm Holdings Corporation. The Brain Cancer Diagnostics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Brain Cancer Diagnostics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Brain Cancer Diagnostics Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Brain Cancer Diagnostics companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Brain Cancer Diagnostics markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Brain Cancer Diagnostics Market Competitive Benchmarking and Company Analysis

Leading companies in Brain Cancer Diagnostics industry include- GE HealthCare, Siemens Healthineers AG, Koninklijke Philips N.V., Roche Diagnostics (F. Hoffmann-La Roche), Thermo Fisher Scientific Inc., Illumina, Inc., Abbott Laboratories, Agilent Technologies, Inc., Hologic, Inc., Fujifilm Holdings Corporation. The Brain Cancer Diagnostics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Brain Cancer Diagnostics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Brain Cancer Diagnostics market remains one of the strongest-performing segments in the country.
The US Brain Cancer Diagnostics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Brain Cancer Diagnostics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Brain Cancer Diagnostics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Brain Cancer Diagnostics markets

Canada's strong Brain Cancer Diagnostics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Brain Cancer Diagnostics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Brain Cancer Diagnostics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Brain Cancer Diagnostics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Brain Cancer Diagnostics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Brain Cancer Diagnostics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Brain Cancer Diagnostics market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Brain Cancer Diagnostics sales through 2034

France Brain Cancer Diagnostics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Brain Cancer Diagnostics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Brain Cancer Diagnostics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Brain Cancer Diagnostics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Brain Cancer Diagnostics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Brain Cancer Diagnostics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Brain Cancer Diagnostics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Brain Cancer Diagnostics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Brain Cancer Diagnostics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Brain Cancer Diagnostics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Brain Cancer Diagnostics Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Brain Cancer Diagnostics Market Segmentation

By Product
Instruments and Imaging Systems
Reagents, Probes, and Kits
Diagnostic and Testing Services
Software and Maintenance Support
By Diagnostic Test Type
Magnetic Resonance Imaging
Magnetic Resonance Spectroscopy
Computed Tomography
Positron Emission Tomography
Biopsy and Tissue Sampling
Lumbar Puncture
Biomarker and Molecular Testing
By Tumor Type Focus
Primary Brain Tumors
Secondary
By Application
Initial Screening and Clinical Diagnosis
Treatment Monitoring and Response Assessment
Prognostic Biomarker Identification
By End-User
Hospitals and Radiology Departments
Specialized Cancer Treatment & Oncology Centers
Diagnostic Laboratories and Pathology Testing Centers
Academic and Cancer Research Institutes

Top Companies in Brain Cancer Diagnostics Industry

GE HealthCare
Siemens Healthineers AG
Koninklijke Philips N.V.
Roche Diagnostics (F. Hoffmann-La Roche)
Thermo Fisher Scientific Inc.
Illumina, Inc.
Abbott Laboratories
Agilent Technologies, Inc.
Hologic, Inc.
Fujifilm Holdings Corporation

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025